癌痛规范化治疗提高中重度癌痛患者生活质量的临床及护理分析

Clinical and Nursing Analysis of Standardized Treatment of Cancer Pain to Improve the Quality of Life of Patients with Moderate to Severe Cancer Pain

目的探讨癌痛规范化治疗提高中重度癌痛患者生活质量的临床及护理分析。方法方便选择该院在2017年10月-2019年10月收治的83例中重度癌痛患者作为研究对象,按照该院在2018年10月实施癌痛规范化治疗的前后作为分界点,将实施前收治的41例患者作为对照组,将实施后收治的42例患者作为观察组。观察对比两组患者的疼痛情况、不良反应发生情况、生活质量状况。结果观察组患者的疼痛情况评分为(2.84±0.85)分要低于对照组的(4.33±1.21)分,差异有统计学意义(t=6.841,P=0.001),观察组患者的不良反应发生率11.90%为要低于对照组的26.82%,差异有统计学意义(χ^2=7.131,P=0.008),观察组患者的生活质量评分为(49.58±7.36)分要高于对照组的(40.66±6.74)分,差异有统计学意义(t=5.687,P=0.001)。结论对中重度癌痛患者实行癌痛规范化治疗可以有效的提高患者的生活质量,减少不良反应的发生,降低患者的疼痛感受,具有较好的临床效果。

Objective To explore the clinical and nursing analysis of standardized treatment of cancer pain to improve the quality of life of patients with moderate to severe cancer pain.Methods Eighty-three patients with moderate to severe cancer pain who were admitted by the hospital from October 2017 to October 2019 were convenient selected as the research objects.According to the hospital's implementation of standardized treatment for cancer pain in October 2018 as the demarcation point,pre-implementation treatment will be adopted.41 patients served as the control group,and 42 patients admitted after the implementation were used as the observation group.Observe and compare the pain,adverse reactions,and quality of life between the two groups of patients.Results The pain score of the observation group was(2.84±0.85)points,which was lower than that of the control group(4.33±1.21)points,and the difference was statistically significant(t=6.841,P=0.001).The adverse reactions occurrence rate of the observation group was 11.90%,lower than that of the control group 26.82%,and the difference was statistically significant(χ^2=7.131,P=0.008).The quality of life score of the patients in the observation group was(49.58±7.36)points higher than that in the control group(40.66±6.74)points,and the difference was statistically significant(t=5.687,P=0.001).Conclusion The standardized treatment of cancer pain in patients with moderate to severe cancer pain can effectively improve the quality of life of patients,reduce the incidence of adverse reactions,reduce the pain experience of patients,and has good clinical effects.